• 2009

Company Description

Tarsa Therapeutics develops an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.

Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.

  • Manufacturer:

    Science and Engineering
  • Formed:

    2009
  • Company Website:

  • Company E-mail:

  • Company Address:

    8 Penn Center, 1628 John F. Kennedy Boulevard, Suite 1400
    Philadelphia, PA
    United States
  • CEO:

    • George R. Maurer
  • We recognize our sponsors starting at $1 per entry.
    Learn more at https://www.ithistory.org/benefits